Treatment of Apical Thrombus with Apixaban (Eliquis)
For left ventricular apical thrombus, initiate apixaban at 10 mg orally twice daily for 7 days, followed by 5 mg twice daily for at least 3 months, with consideration for extended therapy at either 5 mg or 2.5 mg twice daily based on bleeding risk and thrombus resolution.
Dosing Regimen
Initial Treatment Phase (First 7 Days)
- Apixaban 10 mg orally twice daily 1, 2
- This higher initial dose is the FDA-approved regimen for venous thromboembolism treatment and should be applied to left ventricular thrombus
Maintenance Phase (After 7 Days)
- Apixaban 5 mg orally twice daily 1, 2
- Continue for minimum 3 months
- Monitor thrombus resolution with serial echocardiography (typically every 2-4 weeks initially, then monthly) 3, 4
Extended/Secondary Prevention Phase (After 6 Months)
If thrombus has resolved but underlying cardiac dysfunction persists:
- Either 5 mg twice daily OR 2.5 mg twice daily 1, 5, 2
- The reduced dose (2.5 mg twice daily) is reasonable for extended therapy to balance efficacy with bleeding risk 5, 6
Duration of Therapy
Minimum 3 months of anticoagulation is required, but duration should be guided by:
- Thrombus resolution status: Continue full-dose therapy until documented resolution 7, 8
- Underlying cardiac function: Patients with persistent severe LV dysfunction (EF <35%), apical aneurysm, or extensive akinesis may require indefinite anticoagulation 9, 10
- Reassess at 3 months and 6 months with repeat imaging 7, 8
Evidence Supporting Apixaban Use
While apixaban is not FDA-approved specifically for LV thrombus 2, emerging evidence supports its use:
- Non-inferiority to warfarin demonstrated: Two randomized trials showed apixaban achieved comparable thrombus resolution rates (76-92% at 3 months) with potentially lower bleeding risk 7, 8
- Rapid thrombus resolution: Case series report resolution in 7-28 days (mean 17 days), with some cases resolving within one week 3, 4
- Recent AHA guidance: The American Heart Association's 2024 scientific statement acknowledges DOACs as a reasonable alternative to warfarin for LV thrombus 9
Key Advantages Over Warfarin
- No need for INR monitoring or bridging therapy
- Fixed dosing without titration
- Fewer drug-food interactions
- Can be initiated immediately without parenteral anticoagulation overlap 1
Important Caveats and Monitoring
Dose Reductions
Reduce to 2.5 mg twice daily if patient has ≥2 of the following 2:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
Renal Impairment
- CrCl 15-29 mL/min: Use with extreme caution; consider alternative anticoagulation
- CrCl <15 mL/min or dialysis: Apixaban not recommended 2
Drug Interactions
Reduce dose by 50% when combined with strong dual P-gp and CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) 2
Concomitant Antiplatelet Therapy
If patient requires dual antiplatelet therapy (DAPT) post-MI or post-PCI:
- Continue apixaban at VTE treatment doses (not atrial fibrillation doses)
- Minimize DAPT duration to reduce bleeding risk
- Consider discontinuing aspirin after 3-6 months if clinically appropriate 1
Monitoring Strategy
- Baseline: CBC, renal function, hepatic function, PT/INR 11
- During treatment:
- Hemoglobin/hematocrit every 2-3 days for first 14 days if inpatient 11
- Serial echocardiography to assess thrombus resolution
- Long-term: Reassess need for continued anticoagulation at least annually 5
When Thrombus Persists
If thrombus fails to resolve after 3 months on apixaban:
- Consider switching to dabigatran (some evidence suggests benefit in refractory cases) 12
- Consider switching to warfarin with target INR 2-3 12
- Extend treatment duration rather than immediately switching agents 3, 4
- Evaluate for underlying prothrombotic conditions
Special Populations
Cancer Patients
If LV thrombus occurs in setting of active malignancy:
- LMWH preferred over apixaban for first 3 months 13, 11
- Apixaban acceptable if LMWH contraindicated or patient preference 13
- Extended therapy with reduced-dose apixaban (2.5 mg twice daily) shown effective and safer than full-dose in cancer-associated VTE 6
Heart Failure with Reduced Ejection Fraction
Patients with persistent severe LV dysfunction likely require indefinite anticoagulation even after thrombus resolution, given ongoing thrombotic risk 9, 10